Key result
Recent pharmacological developments in cardiovascular medicine, including novel antiarrhythmics, direct oral anticoagulants, and targeted therapies for heart failure and pulmonary arterial hypertension, provide new options with improved safety and efficacy profiles for cardiac patients.
This review highlights changing trends and future perspectives in major classes of cardiovascular medications relevant to perioperative and intensive care management.
Updates anesthesiologists on evolving CV pharmacotherapy; leaves open prospective validation of emerging agents in perioperative settings.
Cardiac practice involves the application of a range of pharmacological therapies. An anesthesiologist needs to keep pace with the rampant drug developments in the field of cardiovascular medicine for appropriate management in both perioperative and intensive care set-up, to strengthen his/her role as a perioperative physician in practice. The article reviews the changing trends and the future perspectives in major classes of cardiovascular medicine.
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2017) conducted a review in Cardiovascular diseases. Novel cardiovascular medications was evaluated. Recent pharmacological developments in cardiovascular medicine, including novel antiarrhythmics, direct oral anticoagulants, and targeted therapies for heart failure and pulmonary arterial hypertension, provide new options with improved safety and efficacy profiles for cardiac patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: